What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Also looking to the future, Eli Lilly Chairman and CEO David A. Ricks stated, “We advanced orforglipron through four ...

Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly and Company’s LLY stock has risen 9.5% in a month, mainly due to the recent recovery in the pharma sector. The drug ...

Eli Lilly (NYSE:LLY) traded higher Thursday after the pharmaceutical company reported third-quarter results ahead of Wall ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...